Welcome to our dedicated page for Citius Pharmaceuticals news (Ticker: CTXR), a resource for investors and traders seeking the latest updates and insights on Citius Pharmaceuticals stock.
Citius Pharmaceuticals Inc. (CTXR) delivers innovative therapies for critical care needs through its pipeline of novel oncology treatments and anti-infective solutions. This news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives shaping the company's progress.
Access verified information about CTXR's FDA interactions, trial results for therapies like LYMPHIR™ and Mino-Lok®, and partnership announcements. Our curated collection ensures you stay informed about material events without promotional bias, supporting data-driven decision-making in this specialized biopharmaceutical sector.
Key updates include progress reports on late-stage clinical programs, manufacturing expansions, and peer-reviewed research publications. All content undergoes strict verification to maintain compliance with financial disclosure standards while preserving accessibility for both medical and investment audiences.
Bookmark this page for streamlined tracking of CTXR's advancements in targeted immunotherapies and critical care innovations. Combine regular monitoring with professional financial advice to maintain perspective on the company's evolving market position.
Citius Oncology (Nasdaq: CTOR) announced on December 4, 2025 an exclusive distribution agreement with Er-Kim to commercialize LYMPHIR (denileukin diftitox-cxdl) in Turkey and Gulf Cooperation Council countries: Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the United Arab Emirates.
The partnership expands LYMPHIR international availability to 19 markets outside the U.S., using Named Patient Programs where permitted by local law. LYMPHIR is an FDA-approved IL-2 receptor-directed cytotoxin for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy. Under the agreement, Er-Kim will handle sales, marketing and reimbursement while Citius Oncology supplies finished product and provides support.
Citius Oncology (Nasdaq: CTOR) announced the U.S. commercial launch of LYMPHIR™ (denileukin diftitox-cxdl) on Dec 1, 2025 for adult patients with relapsed or refractory Stage I–III cutaneous T‑cell lymphoma (CTCL) after at least one prior systemic therapy.
FDA approval was supported by Pivotal Study 302 showing an ORR 36.2%, 84% of evaluable patients with reduced skin tumor burden, and a median time to response 1.4 months. LYMPHIR has a permanent J‑code (J9161) effective Apr 1, 2025 and a Category 2A recommendation in NCCN Guidelines. U.S. distribution is via specialty distributors and commercial support programs; international rights exclude India, Japan, and parts of Asia.
Citius Oncology (Nasdaq: CTOR) will exhibit at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida, December 6–9, 2025, at Booth #265.
The company will present LYMPHIR (denileukin diftitox-cxdl), an IL-2 receptor-directed fusion protein approved by the FDA for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy. Company representatives will be available throughout the meeting to engage with physicians, researchers and CTCL stakeholders. The press release notes the LYMPHIR launch is on track for Q4 2025.
Citius Oncology (Nasdaq: CTOR) announced a deeper collaboration with Verix to integrate the Verix Tovana AI platform into the commercial launch of LYMPHIR (denileukin diftitox-cxdl). LYMPHIR is FDA approved for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma after ≥1 prior systemic therapy and is expected to be commercially available in the U.S. in Q4 2025.
The initiative builds on distribution partnerships, a permanent reimbursement code (J9161), and inclusion in the NCCN Guidelines. Verix Tovana will use real-world claims, analytics, and machine learning to refine HCP targeting, prioritize prescriber engagement, and support real-time field execution to accelerate launch and market penetration.
Citius Pharmaceuticals (Nasdaq: CTXR) closed a registered direct offering priced at‑the‑market on Oct 21, 2025, issuing 3,973,510 shares (or pre‑funded warrants) plus accompanying common warrants at a purchase price of $1.51 per share/pre‑funded warrant, for aggregate gross proceeds of approximately $6.0 million.
The common warrants are exercisable immediately at $1.40 per share and expire five years from initial exercise. H.C. Wainwright acted as exclusive placement agent. Net proceeds are intended to support the commercial launch of LYMPHIR, related milestone/regulatory payments, development of product candidates, and general corporate purposes. Securities were offered under shelf registration File No. 333-277319.
Citius Pharmaceuticals (Nasdaq: CTXR) announced a registered direct offering to sell 3,973,510 shares (or pre-funded warrants) and accompanying common warrants to buy up to 3,973,510 shares at a purchase price of $1.51 per share, generating approximately $6.0 million in gross proceeds before fees. The common warrants carry a $1.40 exercise price, are exercisable immediately, and expire five years from the initial exercise date. Closing is expected on or about October 21, 2025, subject to customary conditions, with H.C. Wainwright acting as exclusive placement agent. Net proceeds are planned to support the commercial launch of LYMPHIR, product development, milestone and regulatory payments, and general corporate purposes.
Citius Oncology (Nasdaq: CTOR) signed a U.S. distribution services agreement with McKesson (NYSE: MCK) to serve as an authorized distributor of record for LYMPHIR (denileukin diftitox-cxdl).
LYMPHIR is FDA approved for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy. The McKesson agreement completes Citius Oncology's core U.S. distribution network with all three largest pharmaceutical wholesalers, supporting the planned commercial launch in Q4 2025. The company also cites inventory readiness, permanent J-code J9161, NCCN guideline inclusion, and provider and patient education resources as part of its commercialization preparations.
Citius Pharmaceuticals (Nasdaq: CTXR) and Citius Oncology (Nasdaq: CTOR) announced management participation in three investor conferences in October 2025. CTXR management will attend LD Micro Main Event XIX (Oct 19-21, 2025) in San Diego and the Think Equity Conference (Oct 30, 2025) in New York. CTOR management will attend the 2025 Maxim Growth Summit (Oct 22-23, 2025) in New York.
Both companies said investors may request 1-on-1 meetings via the event platforms or by contacting the companies' investor relations teams; CTOR noted scheduled meetings with institutional investors and Maxim senior analysts.
Citius Oncology (Nasdaq: CTOR) finalized an exclusive Master Service Agreement with EVERSANA to support the planned U.S. commercialization of LYMPHIR™ (denileukin diftitox-cxdl) in Q4 2025. EVERSANA will provide an integrated suite of pre- and post-launch services including medical information, pharmacovigilance, revenue cycle management, program management, data and analytics, and channel management. LYMPHIR was approved by the U.S. FDA in August 2024 for relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy. The agreement is exclusive and intended to scale launch operations and market access for LYMPHIR in the United States.
Citius Oncology (NASDAQ: CTOR) has successfully closed its previously announced financing round, consisting of a registered direct offering and concurrent private placement. The company raised $9.0 million in gross proceeds through the sale of 5,142,858 shares of common stock and warrants at a combined price of $1.75 per share.
The offering included unregistered warrants to purchase up to 5,142,858 additional shares at an exercise price of $1.84 per share. These warrants will become exercisable after six months and expire five and a half years from issuance. Maxim Group LLC served as the sole placement agent for the transaction.
FAQ
What is the current stock price of Citius Pharmaceuticals (CTXR)?
What is the market cap of Citius Pharmaceuticals (CTXR)?
